Jinwu Financial News | Zaiding Pharmaceutical (09688) announced that Okela (reptinib) has been approved by the China National Drug Administration to treat adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer.
Okela (reptinib) is a new generation tyrosine kinase inhibitor targeting ROS1 and NTRK carcinogenic factors. The company entered into an exclusive license agreement with Turning Point Therapeutics, Inc. (a wholly-owned subsidiary of Bristol-Myers Squibb) to develop and commercialize reptinib in mainland China (mainland), Hong Kong, and Macau.